Table 1. Characteristics of the enrolled studies on TLR2 polymorphism and cancer.
| First author | Year | Ethnicity | Genotyping method | Source of control | Cancer type | Cases | Control | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA | BA | BB | Total | A% | B% | AA | BA | BB | Total | A% | B% | HWE | ||||||
| (-196 to -174del) | ||||||||||||||||||
| Tahara et al. | 2007 | Asian | AS-PCR | PB | Gastric cancer | 126 | 112 | 51 | 289 | 63.0% | 37.0% | 73 | 65 | 8 | 146 | 72.3% | 27.7% | Y |
| Pandey et al. | 2009 | Asian | PCR | PB | Cervical cancer | 102 | 43 | 5 | 150 | 82.3% | 17.7% | 114 | 35 | 1 | 150 | 87.7% | 12.3% | Y |
| Hishida et al. | 2010 | Asian | PCR | HB | Gastric cancer | 243 | 267 | 73 | 583 | 64.6% | 35.4% | 722 | 730 | 184 | 1636 | 66.4% | 33.6% | Y |
| Srivastava et al. | 2010 | Asian | PCR-RFLP | PB | Gallbladder cancer | 132 | 94 | 6 | 232 | 77.2% | 22.8% | 163 | 87 | 4 | 254 | 81.3% | 18.7% | N |
| Zeng et al. | 2011a | Asian | DHPLC | HB | Gastric cancer | 119 | 110 | 19 | 248 | 70.2% | 29.8% | 187 | 246 | 63 | 496 | 62.5% | 37.5% | Y |
| Nischalk et al. | 2011 | Caucasian | PCR | PB | Hepatocellular carcinoma | 115 | 63 | 11 | 189 | 77.5% | 22.5% | 248 | 92 | 7 | 347 | 84.7% | 15.3% | Y |
| Oliveira et al. | 2012 | Caucasian | PCR-RFLP | PB | Gastric cancer | 116 | 50 | 8 | 174 | 81.0% | 19.0% | 189 | 34 | 2 | 225 | 91.6% | 8.4% | Y |
| Mandal et al. | 2012 | Asian | PCR | PB | Prostate cancer | 135 | 54 | 6 | 195 | 83.1% | 16.9% | 193 | 52 | 5 | 250 | 87.6% | 12.4% | Y |
| Theodoropoulos et al. | 2012 | Caucasian | PCR | PB | Breast cancer | 120 | 113 | 28 | 261 | 67.6% | 32.4% | 432 | 46 | 2 | 480 | 94.8% | 5.2% | Y |
| Singh et al. | 2013 | Asian | PCR | PB | Bladder cancer | 110 | 79 | 11 | 200 | 74.8% | 25.3% | 119 | 73 | 8 | 200 | 77.8% | 22.3% | Y |
| Bi et al. | 2014 | Asian | PCR | PB | Cervical cancer | 40 | 47 | 15 | 102 | 62.3% | 37.7% | 36 | 50 | 14 | 100 | 61.0% | 39.0% | Y |
| Castano-Rodriguez et al. | 2014 | Asian | MassARRAY | HB | Gastric cancer | 7 | 44 | 35 | 86 | 33.7% | 66.3% | 19 | 95 | 106 | 220 | 30.2% | 69.8% | Y |
| Zidi et al. | 2014 | African | PCR | HB | Cervical cancer | 89 | 20 | 13 | 122 | 81.1% | 18.9% | 196 | 37 | 27 | 260 | 82.5% | 17.5% | N |
| Devi et al. | 2015 | Asian | PCR | PB | Breast cancer | 251 | 191 | 20 | 462 | 75.0% | 25.0% | 491 | 246 | 33 | 770 | 79.7% | 20.3% | Y |
| Proenca et al. | 2015 | African | PCR | PB | Colorectal cancer | 144 | 39 | 5 | 188 | 87.0% | 13.0% | 200 | 36 | 4 | 240 | 90.8% | 9.2% | Y |
| Zidi et al. | 2015 | African | PCR | PB | Cervical cancer | 93 | 26 | 11 | 130 | 81.5% | 18.5% | 196 | 37 | 27 | 260 | 82.5% | 17.5% | N |
| AL-Harras et al. | 2016 | African | PCR-RFLP | PB | Breast cancer | 44 | 22 | 6 | 72 | 76.4% | 23.6% | 61 | 33 | 6 | 100 | 77.5% | 22.5% | Y |
| Huang et al. | 2018 | Asian | PCR | PB | Gastric cancer | 105 | 124 | 31 | 260 | 64.2% | 35.8% | 132 | 113 | 15 | 260 | 72.5% | 27.5% | Y |
| rs3804099 | ||||||||||||||||||
| Etokebe et al. | 2009 | Caucasian | TaqMan | PB | Breast cancer | 29 | 44 | 16 | 89 | 57.3% | 42.7% | 26 | 48 | 15 | 89 | 56.2% | 43.8% | Y |
| Slattery et al. | 2012 | Caucasian | GoldenGate | PB | Colon cancer | 1255 | 300 | 1555 | - | - | 1531 | 425 | 1956 | - | - | - | ||
| Xie et al. | 2012 | Asian | SNaPshot | HB | Hepatocellular carcinoma | 19 | 71 | 121 | 211 | 25.8% | 74.2% | 15 | 117 | 100 | 232 | 31.7% | 68.3% | N |
| Miedema et al. | 2012 | Caucasian | AS-PCR | HB | Lymphoblastic leukemia | 51 | 94 | 37 | 182 | 53.8% | 46.2% | 48 | 102 | 28 | 178 | 55.6% | 44.4% | N |
| Slattery et al. | 2012 | Caucasian | GoldenGate | PB | Rectal cancer | 238 | 372 | 144 | 754 | 56.2% | 43.8% | 299 | 477 | 183 | 959 | 56.0% | 44.0% | Y |
| Zeljic et al. | 2013 | Caucasian | TaqMan | PB | Oral cancer | 29 | 39 | 25 | 93 | 52.2% | 47.8% | 37 | 67 | 0 | 104 | 67.8% | 32.2% | N |
| Semlali et al. | 2017 | Asian | TaqMan | PB | Breast cancer | 35 | 58 | 32 | 125 | 51.2% | 48.8% | 33 | 71 | 42 | 146 | 46.9% | 53.1% | Y |
| Semlali et al. | 2018 | Asian | TaqMan | PB | Colon cancer | 42 | 50 | 19 | 111 | 60.4% | 39.6% | 28 | 47 | 27 | 102 | 50.5% | 49.5% | Y |
| Tongtawee et al. | 2018 | Asian | TaqMan | HB | Gastric cancer | 62 | 13 | 13 | 88 | 77.8% | 22.2% | 194 | 56 | 62 | 312 | 71.2% | 28.8% | N |
| Zeng et al. | 2011b | Asian | PCR-RFLP | HB | Gastric cancer | 132 | 99 | 17 | 248 | 73.2% | 26.8% | 216 | 231 | 49 | 496 | 66.8% | 33.2% | Y |
| rs3804100 | ||||||||||||||||||
| Purdu et al. | 2008 | Caucasian | TaqMan | PB | Non-Hodgkin lymphoma | 1658 | 272 | 12 | 1942 | 92.4% | 7.6% | 1556 | 233 | 9 | 1798 | 93.0% | 7.0% | Y |
| Etokebe et al. | 2009 | Caucasian | TaqMan | PB | Breast cancer | 76 | 13 | 0 | 89 | 92.7% | 7.3% | 84 | 11 | 0 | 95 | 94.2% | 5.8% | Y |
| Xie et al. | 2012 | Asian | SNaPshot | HB | Hepatocellular carcinoma | 14 | 67 | 130 | 211 | 22.5% | 77.5% | 11 | 110 | 111 | 232 | 28.4% | 71.6% | N |
| Miedema et al. | 2012 | Caucasian | AS-PCR | HB | Lymphoblastic leukemia | 170 | 18 | 1 | 189 | 94.7% | 5.3% | 165 | 18 | 0 | 183 | 95.1% | 4.9% | Y |
| Castano-Rodriguez et al. | 2014 | Asian | MassARRAY | HB | Gastric cancer | 47 | 34 | 4 | 85 | 75.3% | 24.7% | 122 | 76 | 14 | 212 | 75.5% | 24.5% | Y |
| Semlali et al. | 2017 | Asian | TaqMan | PB | Breast cancer | 99 | 24 | 1 | 124 | 89.5% | 10.5% | 115 | 27 | 4 | 146 | 88.0% | 12.0% | Y |
| Semlali et al. | 2018 | Asian | TaqMan | PB | Colon cancer | 99 | 13 | 2 | 114 | 92.5% | 7.5% | 82 | 19 | 2 | 103 | 88.8% | 11.2% | Y |
| Tongtawee et al. | 2018 | Asian | TaqMan | HB | Gastric cancer | 66 | 22 | 0 | 88 | 87.5% | 12.5% | 230 | 70 | 12 | 312 | 84.9% | 15.1% | N |
| rs4696480 | ||||||||||||||||||
| Miedema et al. | 2012 | Caucasian | AS-PCR | HB | Hepatocellular carcinoma | 42 | 99 | 44 | 185 | 49.5% | 50.5% | 60 | 83 | 38 | 181 | 56.1% | 43.9% | Y |
| Gallo et al. | 2017 | Caucasian | TaqMan | PB | Oral cancer | 12 | 39 | 24 | 75 | 42.0% | 58.0% | 31 | 34 | 24 | 89 | 53.9% | 46.1% | N |
| Semlali et al. | 2017 | Asian | TaqMan | PB | Breast cancer | 46 | 51 | 29 | 126 | 56.7% | 43.3% | 50 | 63 | 25 | 138 | 59.1% | 40.9% | Y |
| Semlali et al. | 2018 | Asian | TaqMan | PB | Colon cancer | 30 | 49 | 27 | 106 | 51.4% | 48.6% | 26 | 41 | 25 | 92 | 50.5% | 49.5% | Y |
| rs5743708 | ||||||||||||||||||
| Nischalk et al. | 2011 | Caucasian | PCR | PB | Hepatocellular carcinoma | 174 | 15 | 0 | 189 | 96.0% | 4.0% | 319 | 28 | 0 | 347 | 96.0% | 4.0% | Y |
| Slattery et al. | 2012 | Caucasian | GoldenGate | PB | Rectal cancer | 727 | 27 | 754 | - | - | 913 | 46 | 959 | - | - | |||
| Slattery et al. | 2012 | Caucasian | GoldenGate | PB | Colon cancer | 1467 | 88 | 1555 | - | - | 1864 | 92 | 1956 | - | - | |||
| Kina et al. | 2018 | Caucasian | PCR | PB | Glioma | 32 | 18 | 70 | 120 | 34.2% | 65.8% | 184 | 35 | 6 | 225 | 89.6% | 10.4% | N |
| rs1898830 | ||||||||||||||||||
| Xie et al. | 2012 | Asian | SNPshot | HB | Hepatocellular carcinoma | 47 | 92 | 72 | 211 | 44.1% | 55.9% | 34 | 118 | 80 | 232 | 40.1% | 59.9% | Y |
| Slattery et al. | 2012 | Caucasian | GoldenGate | PB | Rectal cancer | 305 | 363 | 86 | 754 | 64.5% | 35.5% | 410 | 437 | 111 | 958 | 65.6% | 34.4% | Y |
| Slattery et al. | 2012 | Caucasian | GoldenGate | PB | Colon cancer | 705 | 674 | 176 | 1555 | 67.0% | 33.0% | 896 | 833 | 227 | 1956 | 67.1% | 32.9% | Y |
Abbreviations: H-B, hospital based; P-B, population based. P>0.05 means conformed to HWE.